Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model (2022)
- Authors:
- USP affiliated authors: PEREIRA, MAURÍCIO DOS SANTOS - FMRP ; MARANGONI, GLAUCE CRIVELARO DO NASCIMENTO - FORP ; BORTOLANZA, MARIZA - FMRP ; GUIMARAES, ELAINE APARECIDA DEL BEL BELLUZ - FORP
- Unidades: FMRP; FORP
- DOI: 10.3389/fphar.2022.1045465
- Subjects: NEUROLOGIA; INFLAMAÇÃO; CITOCINAS
- Keywords: Neuroinflammation; Cytokines; Tetracyclines; Parkinson’s disease; IL-1β; TNF-α; PGE2; COX-2
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Frontiers in Pharmacology
- ISSN: 1663-9812
- Volume/Número/Paginação/Ano: v. 13, on-line, 2022
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
PEREIRA, Maurício dos Santos et al. Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model. Frontiers in Pharmacology, v. 13, 2022Tradução . . Disponível em: https://doi.org/10.3389/fphar.2022.1045465. Acesso em: 28 dez. 2025. -
APA
Pereira, M. dos S., Nascimento, G. C. do, Bortolanza, M., Michel, P. P., Raisman-Vozari, R., & Del Bel, E. A. (2022). Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model. Frontiers in Pharmacology, 13. doi:10.3389/fphar.2022.1045465 -
NLM
Pereira M dos S, Nascimento GC do, Bortolanza M, Michel PP, Raisman-Vozari R, Del Bel EA. Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model [Internet]. Frontiers in Pharmacology. 2022 ; 13[citado 2025 dez. 28 ] Available from: https://doi.org/10.3389/fphar.2022.1045465 -
Vancouver
Pereira M dos S, Nascimento GC do, Bortolanza M, Michel PP, Raisman-Vozari R, Del Bel EA. Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model [Internet]. Frontiers in Pharmacology. 2022 ; 13[citado 2025 dez. 28 ] Available from: https://doi.org/10.3389/fphar.2022.1045465 - Doxycycline and its derivative, COL‐3, decrease dyskinesia induced by L-DOPA in hemiparkinsonian rats
- Management with antibiotics in Parkinson's disease
- Rifampicin and its derivative Rifampicin quinone reduce microglial inflammatory responses and neurodegeneration induced in vitro by α-Synuclein fibrillary aggregates
- The chemically-modified tetracycline COL-3 and its parent compound doxycycline prevent microglial inflammatory responses by reducing glucose-mediated oxidative stress
- Interferon-γ involvement in the neuroinflammation associated with Parkinson’s disease and L-DOPA-induced dyskinesia
- CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects
- Contributive role of TNF-α to L-DOPA-induced dyskinesia in a unilateral 6-OHDA lesion model of parkinson’s disease
- Contributive role of TNF-α to L-DOPA-induced dyskinesia in a unilateral 6-OHDA lesion model of Parkinson's disease
- Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats
- Nociceptive response to L-DOPA-induced dyskinesia in hemiparkinsonian rats
Informações sobre o DOI: 10.3389/fphar.2022.1045465 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003268821.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
